经中国证券监督管理委员会《关于同意湖北华强科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2021]3368 号）同意注册，并经上海证券交易 所同意，湖北华强科技股份有限公司（以下简称"公司"）于 2021 年 12 月 6 日在上海证券交易所科创板上市。公司聘请了华泰联合证券有限责任公司（以下 简称"华泰联合证券"）担任公司首次公开发行股票并在科创板上市的保荐机构， 华泰联合证券对公司的持续督导期至 2024 年 12 月 31 日。因前述期限届满后公 司募集资金尚未使用完毕，华泰联合证券对未使用完毕的募集资金使用情况继续 履行持续督导义务。 经与各方友好协商一致，公司于 2025 年 7 月 8 日召开的第二届董事会第十 二次会议审议通过了《关于变更持续督导保荐机构和保荐代表人的议案》《关于 变更保荐机构后重新签订募集资金三方监管协议的议案》，同意公司持续督导保 荐机构由华泰联合证券变更为长江证券承销保荐有限公司（以下简称"长江保 荐"），并重新签订募集资金三方监管协议，同时董事会授权公司管理层办理持 续督导协议、募集资金三方监管协议签署等相关事宜。 公司将与长江保荐签订《持续督导协议》，长江保 ...

证券代码：688151 证券简称：华强科技 公告编号：2025-031 湖北华强科技股份有限公司 第二届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 湖北华强科技股份有限公司（以下简称"公司"）于 2025 年 7 月 8 日以现场 结合视频会议的方式在公司会议室召开第二届董事会第十二次会议。本次会议的 通知于 2025 年 7 月 3 日通过电子邮件方式送达全体董事。本次会议由董事长孙 光幸先生主持，应出席董事 9 名，实际出席董事 9 名，公司监事、高级管理人员 列席了会议。本次会议的召集和召开符合《中华人民共和国公司法》、《中华人民 共和国证券法》《湖北华强科技股份有限公司章程》《湖北华强科技股份有限公司 董事会议事规则》等有关法律、法规、规范性文件的规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事审议，做出以下决议： （一）审议通过《关于变更持续督导保荐机构和保荐代表人的议案》 公司董事会同意《关于变更持续督导保荐机构和保荐代表人的议案》，并授 权 ...

Group 1 - The military equipment restructuring concept declined by 1.49%, ranking among the top declines in the concept sector, with companies like Zhongguangxue, Huachuang Technology, and Hunan Tianyan experiencing significant drops [1][2] - Among the stocks in the military equipment restructuring concept, only two stocks saw price increases, with Changcheng Military Industry and Changan Automobile rising by 3.04% and 0.08% respectively [1][2] - The military equipment restructuring concept experienced a net outflow of 554 million yuan from main funds today, with six stocks seeing net outflows, and five stocks having outflows exceeding 10 million yuan [2] Group 2 - Hunan Tianyan had the highest net outflow of main funds at 262 million yuan, followed by Changcheng Military Industry, Huachuang Technology, and Zhongguangxue with net outflows of 155 million yuan, 52.29 million yuan, and 50.06 million yuan respectively [2] - The trading volume for Hunan Tianyan was 24.89%, while Changcheng Military Industry had a trading volume of 17.18% [2] - The military equipment restructuring concept saw a mix of performance, with some stocks like Changan Automobile showing slight gains despite the overall decline in the sector [1][2]

New Stock Issuance - The new stock "同宇新材" (code: 301630) is listed at an issuance price of 84.00[1] - "信通电子" (code: 001388) has an issuance price of 16.42[1] Rights Issues and Announcements - "济川药业" (code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - "中程退" (code: 300208) has 13 trading days remaining until the last trading day[1] - "退市锦港" (code: 600190) also has 13 trading days remaining until the last trading day[1] - "恒立退" (code: 000622) has 10 trading days remaining until the last trading day[1] Abnormal Fluctuations - "浙江东日" (code: 600113) reported severe abnormal fluctuations[1] - "汇金股份" (code: 300368) is noted for abnormal fluctuations[3]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - The closing price of Huachuang Technology (688151) on June 30 was 28.19 yuan, representing a 17.17% increase, with a turnover rate of 7.80% and an amplitude of 19.25%, resulting in a transaction volume of 715 million yuan [2] - The stock was listed on the daily trading list due to its closing price increase of 15% [2] - The top five trading departments accounted for a total transaction of 84.55 million yuan, with a net sell of 17.58 million yuan [2] Group 2 - The main capital inflow for the stock was 38.99 million yuan throughout the day [3] - The largest buying department was Goldman Sachs (China) Securities, with a purchase amount of 8.58 million yuan, followed by Guosen Securities with 6.94 million yuan [3] - The largest selling department was Guojin Securities, with a selling amount of 12.98 million yuan [3]

Group 1 - The core viewpoint of the news is that the military equipment restructuring concept has seen a significant increase of 8.89%, leading the concept sector in terms of growth [1][2] - Within the military equipment restructuring concept, seven stocks experienced gains, with notable performances from Hunan Tianyan, Zhongguang Optical, and Changcheng Military Industry, which all hit the daily limit [1][2] - The top gainers in the sector included Hunan Tianyan with a rise of 10.04%, Changcheng Military Industry at 10.00%, and Zhongguang Optical also at 10.00% [3] Group 2 - The military equipment restructuring concept attracted a net inflow of 590 million yuan from main funds, with Hunan Tianyan receiving the highest net inflow of 271 million yuan [2][3] - The net inflow ratios for Hunan Tianyan, Changcheng Military Industry, and Huaqing Technology were 20.22%, 9.65%, and 5.45% respectively, indicating strong investor interest [3]

截至2025年6月30日 13:30，上证科创板综合指数(000680)强势上涨1.51%，成分股翔宇医疗(688626)上涨 20.01%，华强科技(688151)上涨16.29%，晶品特装(688084)上涨15.29%，毕得医药(688073)，药康生物 (688046)等个股跟涨。科创综指ETF(589680)上涨1.56%，最新价报0.98元。 科创综指ETF(589680)，场外联接A：023757；联接C：023758；联接I：024141。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 民生证券称，AI应用百花齐放，医疗、司法、金融、教育等具备广阔落地潜力。随着国产模型、国产 算力生态成熟，AI应用在多个垂直场景有望加速落地。以医疗为例，6月26日，蚂蚁集团推出全新的AI 健康应用"AQ"。基于蚂蚁的医疗大模型，AQ提供健康科普、就诊咨询、报告解读、健康档案等AI功 能，连接了全国超5000家医院、近百万医生、近200个名医AI分身等医疗服务。阿里、蚂蚁、字节、腾 讯等国内科技巨头纷纷入局，以模型能力为基石，联合拥有深刻行业Know-how的IT厂商，加速推进AI 应 ...

Core Insights - The total margin financing balance on the STAR Market increased by 1.26 billion yuan compared to the previous trading day, while the margin short selling balance decreased by 5.71 million yuan [1] - As of June 26, the total margin balance on the STAR Market reached 157.09 billion yuan, marking a continuous increase for four consecutive trading days [1] - The highest margin financing balance was recorded for SMIC at 7.17 billion yuan, followed by Cambrian and Haiguang Information with balances of 4.52 billion yuan and 3.50 billion yuan respectively [1] Margin Financing Summary - 359 stocks on the STAR Market saw an increase in margin financing balance, while 225 stocks experienced a decrease [1] - Notable increases in margin financing balance were observed for Haooubo (29.57%), Huachuang Technology (28.45%), and Beiqing Song (24.44%) [1][2] - The largest decreases were seen in Delong Laser (-12.32%), Changying Tong (-10.57%), and Sitwei (-10.27%) [1][2] Margin Short Selling Summary - The highest margin short selling balance was for Haiguang Information at 1.8 million yuan, followed closely by SMIC and Cambrian at 1.6 million yuan and 1.6 million yuan respectively [2] - 93 stocks on the STAR Market reported an increase in margin short selling balance, while 176 stocks saw a decrease [2] - Significant increases in margin short selling balance were noted for Maixinlin (96.41%), Tianzhun Technology (69.57%), and Anheng Information (62.26%) [2][3] - The largest decreases were recorded for Huaxing Yuanchuang (-51.21%), Huazhu Gaoke (-50.61%), and Chipengwei (-46.64%) [2][3]

证券代码：688151 证券简称：华强科技 公告编号：2025-029 湖北华强科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 湖北华强科技股份有限公司（以下简称"公司"）股票交易连续两个交 易日内（2025 年 6 月 25 日、2025 年 6 月 26 日）日收盘价格涨幅偏离值累计达 到 30%，根据《上海证券交易所科创板股票上市规则》（以下简称"《科创板上 市规则》"）、《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易 实时监控细则》的有关规定，属于股票交易异常波动情形。 经公司自查，并向控股股东、实际控制人函证确认，截至本公告披露日， 公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大事项， 也不存在处于筹划阶段的重大事项。 截至 2025 年 6 月 26 日，公司收盘价为 26.17 元/股，根据中证指数有 限公司发布的公司最新市盈率为 400.20 倍，最新滚动市盈率为 878.32 倍，公 司所处的医药制造业最近一个月平均滚动 ...